Ten of 83: One Holder Is 60.7% of the Superinvestors' CVS Health Stake. Its Insiders Filed Nothing in 90 Days.

GetCoattail Research — The Filing Tape #75. CVS Health is the most-searched company name in the United States today, and the filings describe a register held by ten of our tracked superinvestors — three-fifths in one portfolio — a full market that added 153.6 million shares, an insider record silent for a quarter, and a borrow of just 1.26% of the share count.

The Hype

CVS Health is the stock name at the top of today's search list: on Google Trends' United States list, "cvs" drew 1,000+ searches, the largest volume on the list and the only entry that names a listed company. The news flow explains the attention. On October 13 the Justice Department announced a $315 million settlement resolving its case over opioid prescriptions filled at CVS pharmacies; the company said it disagreed with the allegations and admitted no wrongdoing. The operating story arrived earlier: second-quarter results on August 5 showed revenue of $106.1 billion, up 7.3% year over year, adjusted earnings per share of $2.58 against a consensus near $1.87, and guidance raised to $7.90–$8.10. Cardinal Health extended its distribution agreement with CVS through June 2032 on October 1. MarketBeat's consensus is a moderate buy at $107.80; Leerink cut its target from $119 to $112 on October 12 while keeping an outperform rating. Results are due November 4. The price round-tripped part of the story: on our daily-close file it rose from $71.82 at March 31, 2026 to $103.45 at June 30 — up 44.0% — reached $110.60 on July 21, and last closed at $86.46 on October 2, down 21.8% from that high. The filings answer who held the stock through the rise, and who has filed anything since.

The Tape

For CVS Health — the seventy-fifth Filing Tape audit — the tape shows a ten-name tracked cohort whose share count barely moved in a quarter when the price rose 44.0%, a full market adding 225 filers and 153.6 million shares, an insider window with no filing in ninety days, no recorded congressional trade, a passive-only 5% register whose maximum dates to June 2025, and a borrow shrinking for two years.

Lens 1 — the superinvestors: ten holders, one of them three-fifths of the position. We track 83 large, mostly long-only managers whose 13F portfolios we collect directly from SEC EDGAR. As of June 30, 2026, 10 held CVS Health long, totalling 82,386,660 shares worth $8,522,911,300, with no option rows. Dodge & Cox Funds holds 50,012,765 shares worth $5,173,820,539 — 60.7% of the cohort's position — at a 2.71% weight, labelled decreased, down 3.4%. Next are Davis Advisors (11,865,916 shares, decreased) and Pzena Investment Management (11,769,536 shares, decreased 14.5%). Six of the ten decreased, two were unchanged, one increased (Ariel Investments, up 4.0% to 730,110 shares) and one is new: Viking Global Investors, with 3,663,361 shares. Two managers exited — Maverick Capital and Tweedy Browne — but their prior positions were 9,472 and 19,132 shares, so the exits are footnotes. On the pipeline's holdings files, the cohort held 83,160,512 shares in 11 rows at March 31 and 82,386,660 at June 30 — down 773,852 shares (-0.93%) in the quarter the price rose 44.0%. The implied price, $103.45, sits exactly on the June 30 close. 13F figures are as of June 30, 2026; funds have up to 45 days to file, so this picture is complete — and always lagging.

Lens 2 — institutions: 225 more filers, 153.6 million more shares. At June 30, 2026, 2,075 institutions reported positions, up 225 from 1,850 at March 31 (+12.16%), 2,062 of them long. Reported shares rose 15.72%, from 977,005,745 to 1,130,618,041 shares. Reported value rose 66.15% to $114,988,606,536; the aggregate includes option rows, so we headline filer and share counts and label dollars "reported" (see methodology). Where the tracked cohort stood still, the full market broadened.

Lens 3 — insiders: no filing at all in ninety days. The parsed Form 4 record holds 82 filings through October 2, 2026. The last 90 days hold zero filings — no purchases, no sales, by anyone. The last year holds 48 filings with 4 purchase transactions totalling just 104 shares and $5,877.40, by 2 buyers, all four of them officer purchases — against 8 sale transactions totalling 3,441,551 shares and $323,701,514.75, by 2 sellers, one of them an officer sale. Across the full record, purchases total 6 transactions (31,674 shares, $2,106,886.40, 4 buyers) against 16 sales (7,206,564 shares, $578,428,065.33, 4 sellers). The one-year purchase total is so small that its implied price, $56.51, sits below the window's traded range on our price file; we cite it as reported and flag that in the methodology. We assign no motives — here there is not even a recent act to describe.

Lens 4 — Congress: no recorded trade. The combined record (as of October 3, 2026), the House aggregate (October 3, 2026) and the Senate aggregate (October 1, 2026) each carry no entry at all for this ticker. This audit reports that as no recorded trade in the aggregates we maintain.

Lens 5 — the 5% register: six filings, all passive, and the maximum is a year old. Our full parse holds exactly 6 SC 13D/G filings — two SC 13G and four SC 13G/A, with four amendments and no SC 13D-family filing at all — 6 reporting-person rows across 5 names, most recently filed August 13, 2026, matching the site aggregate's ticker-keyed row on every headline field. The register's maximum is BlackRock, Inc. reporting 105,292,588 shares (8.3%) as of June 30, 2025 — up from 89,218,268 shares (7.1%) as of March 31, 2025. The most recent filing is Dodge & Cox reporting 50,012,765 shares (3.9%) as of June 30, 2026 — the same share count as its tracked 13F position in Lens 1. The Vanguard rows change reporting entity as filed: The Vanguard Group reports 0 shares (0.0%) as of March 13, 2026, and Vanguard Capital Management then reports 95,598,528 shares (7.51%) as of March 31, 2026. Capital World Investors reports 68,785,990 shares (5.5%) as of March 31, 2025.

Lens 6 — short interest: 16,123,980 shares, and falling for two years. As of September 15, 2026 — the most recent of 137 FINRA settlements since January 15, 2021 — 16,123,980 shares were sold short, down 10.99% from the prior settlement. The series maximum, 42,521,469 shares on January 12, 2024 — verified by a maximum query over the whole series — is nearly three years old, and the latest sits 62.1% below it. The last five settlements read 19,524,883, 18,676,470, 16,823,735, 18,114,651 and 16,123,980. Against the year-ago 23,623,517 shares the latest is down 31.7%; against the June 30, 2026 settlement of 19,938,997 it is down 19.1%. Against 1,278,970,369 shares outstanding, it is 1.26% of the share count, at 3.14 days to cover.

The Gap

The narrative describes a group that beat its quarter, raised guidance, extended a distribution contract to 2032 — and then, this week, settled a federal opioid case for $315 million, with a target cut and a November 4 earnings date ahead. The filings describe positioning that did not chase the second-quarter rise. The full market held 1,130,618,041 reported shares at June 30, up 153,612,296 shares (+15.72%), as its filer count rose by 225 to 2,075. The tracked cohort held 82,386,660 shares, down 0.93%, with six of ten holders decreasing and 60.7% of the position in Dodge & Cox alone — a holder that itself trimmed 3.4%. The 5% register holds no active filing and no print newer than August; its maximum, BlackRock's 8.3%, dates to June 2025. Insiders filed nothing at all in the ninety days to October 2, after a year in which recorded purchases totalled 104 shares. Congress records nothing at all. And the borrow, at 16,123,980 shares and 1.26% of the share count, is a third smaller than a year ago and nearly two-thirds below its January 2024 record. One plausible reading is that the broad register absorbed the rise while the tracked cohort, the insiders and the shorts all stood aside in different ways. The record supports each clause separately; it does not say which side the next quarter favours.

What Would Change the Picture

Nothing above is a recommendation. It is a record. These filings would change the description:

• 1. The 2026Q3 13Fs (filing window closing mid-November 2026). The cohort held 82,386,660 shares at June 30 — ten holders, 60.7% in Dodge & Cox. Dodge & Cox adding after its 3.4% trim, or the holder count moving off ten, rewrites this lens either way.
• 2. A first insider filing of any kind after the silent quarter. The record holds zero filings in the ninety days through October 2, 2026, and one-year purchases of 104 shares. One purchase — or one sale — breaks the silence.
• 3. A first SC 13D, or a fresh print from BlackRock or Vanguard Capital Management. BlackRock's 8.3% dates to June 30, 2025 and Vanguard Capital Management's 7.51% to March 31, 2026. A step by either, or the register's first active filing, restarts this lens.
• 4. Whether the borrow keeps shrinking, or rebuilds. Short interest stands at 16,123,980 shares, 62.1% below the January 12, 2024 record of 42,521,469. A reading back above the July 15 print of 19,524,883 extends a rebuild; a reading below the series minimum of 10,200,224 sets a new series low.
• 5. A first recorded congressional trade of any kind. The combined, House and Senate aggregates all carry no entry for this ticker. One recorded trade gives this lens its first print.

Until one of those prints, the record describes a stock held by ten of our 83 tracked superinvestors — 82,386,660 shares, three-fifths in one portfolio — whose insiders filed nothing in a full quarter, whose 5% register is passive-only, and whose borrow has faded since January 2024.

As-of & Limits

The lenses rest on different clocks, none live: 13F is a June 30, 2026 snapshot published up to 45 days later; Form 4 runs through October 2, 2026; Congress through October 3, 2026 (Senate October 1); 13D/G through the August 13, 2026 filing; short interest through September 15, 2026; prices end October 2, 2026. Three limits are specific to this name: the site's insider aggregate carries no row for this ticker, so the insider lens rests on the full Form 4 parse alone; the one-year insider purchase total (104 shares, $5,877.40) implies a price below the window's traded range on our price file, and is cited as reported rather than explained; and the October news above — the settlement, the target cut and the coming earnings date — postdates every lens here except the search list itself.

Related reading: One of 83: Lone Pine Opened a New Nebius Position in Q2. Short Interest Is 18.49% of the Share Count. — Filing Tape #74; Two of 83: Viking Opened a New Take-Two Position in Q2. Its Insiders Have Never Bought a Share. — Filing Tape #73; Four of 83: Every Superinvestor in Corning Cut in Q2 While the Full Market Added 103 Million Shares. Its Insiders Have Never Bought a Share. — Filing Tape #72. CVS Health's own page: CVS Health Corporation (CVS) on GetCoattail.

Methodology and data notes

• Superinvestor lens: 83 managers collected directly from SEC EDGAR Form 13F (managers_13f collection), positions as of June 30, 2026; CVS Health identified by CUSIP 126650100. Ten distinct managers hold long positions totalling 82,386,660 shares; there are no option rows for this name in the collection. The direction count on the collection's labels, across the long rows, is six DECREASED (Dodge & Cox Funds, Christopher Davis - Davis Advisors, Richard Pzena - Pzena Investment Management, Samantha McLemore - Patient Capital Management, Bill Nygren - Oakmark Funds, Hillman Capital Management), two UNCHANGED (Prem Watsa - Fairfax Financial Holdings, David Katz - Matrix Asset Advisors), one INCREASED (John Rogers - Ariel Investments) and one NEW (Viking Global Investors); the collection's exit list contains two CVS Health rows (Lee Ainslie - Maverick Capital, 9,472 prior shares; Tweedy Browne, 19,132 prior shares). Quarter-to-quarter cohort totals (83,160,512 long shares at March 31, in 11 rows; 82,386,660 long shares at June 30, a change of -773,852 shares or -0.93%) are from the site pipeline's holdings files on the same CUSIP basis in both quarters, and the pipeline's second-quarter totals match the EDGAR collection exactly on both shares and value (differences of 0 shares and $0). Dodge & Cox's share of the cohort is 60.7% = 50,012,765 / 82,386,660.
• Full-market lens: SEC Form 13F Data Sets full-market aggregation. The primary table is the full13f collection's by-ticker file (holders = distinct filers reporting the CUSIP; 2,062 reported long positions out of 2,075 filers). CVS Health reports under a single CUSIP, 126650100, and the backfill fixtures' by-CUSIP row matches the by-ticker row exactly on holders, shares, reported value, prior holders and prior value. The by-ticker file's entered/exited fields (1,631 and 1,406, a net of +225 that matches the change in holder count) are gross flows, so this audit headlines the net change. Reported-value caution: the aggregate value ($114,988,606,536 over 1,130,618,041 shares) implies $101.70 per share against a June 30, 2026 close of $103.45 in our price file, a gap of -1.7% — printed here as found. The aggregate sums the VALUE of every information-table row — including put and call option rows — while the share count covers long common-stock rows only, so we headline filer and share counts and label dollar values "reported."
• Insider lens: full-parse Form 4 aggregation (agg_by_ticker), record as of October 2, 2026 (82 filings). Sale and purchase counts are transaction-code counts (S and P) in non-derivative rows; grants and exercises are not counted as purchases, and one filing can contain many transaction rows. The 90-day window (July 5 to October 2, 2026) holds zero filings and therefore zero purchase and zero sale transactions (0 shares, $0, zero buyers and zero sellers, officer transactions likewise zero). Purchase transactions total 4 in the last year (104 shares, $5,877.40, 2 buyers, all four recorded as officer purchases) and 6 across the parsed record (31,674 shares, $2,106,886.40, 4 buyers, four of them officer purchases); sale transactions total 8 in the last year (3,441,551 shares, $323,701,514.75, 2 sellers, one of them an officer sale) and 16 across the record (7,206,564 shares, $578,428,065.33, 4 sellers, two of them officer sales). The site's insider aggregate (compiled as of October 14, 2026) carries no row for this ticker at all, so no site-versus-parse cross-check exists for this name and this audit headlines the full parse throughout. The full-parse aggregate's sale-value totals imply $94.06 per share for the one-year window and $80.26 for the full record, each inside the traded price range of its window on our price file ($70.08 to $110.60 for the one-year window, and $43.78 to $110.83 across the price file), so the sale totals are cited as figures in this article. The one-year purchase total implies $56.51 per share, below that window's traded range on our price file; the purchase figures are therefore cited as reported in the aggregate, with the gap flagged here rather than explained.
• 13D/G lens: full-parse SC 13D/G parsed filings (6 filings matching issuer CIK 64803 on CUSIP 126650100, 6 reporting-person rows across 5 names as filed: two SC 13G filings and four SC 13G/A amendments, with no SC 13D-family filing), filings through August 13, 2026. The site aggregation carries this name under a ticker-keyed row; that row (6 filings, 0 D-filings, 6 G-filings, 4 amendments, 5 reporters, latest date August 13, 2026, maximum 8.3% and 408,908,139.0 reported shares) matches the parsed filings on filings, form mix, amendments, latest date, maximum and reported-share total. The parsed reporting-person rows sum to 408,908,139.0 shares, but that total sums reporting-person rows across different dates, so it is not used as a stake figure in the article. BlackRock, Inc.'s chain (89,218,268 shares at 7.1% as of March 31, 2025; 105,292,588 shares at 8.3% as of June 30, 2025), the Vanguard rows (The Vanguard Group printing 0 shares at 0.0% as of March 13, 2026, filed March 26, 2026 as SC 13G/A; Vanguard Capital Management printing 95,598,528 shares at 7.51% as of March 31, 2026, filed April 29, 2026 as SC 13G), Capital World Investors (68,785,990 shares at 5.5% as of March 31, 2025) and Dodge & Cox (50,012,765 shares at 3.9% as of June 30, 2026, filed August 13, 2026 — the same share count as the Dodge & Cox 13F position in the superinvestor lens) are reported as filed, under the names exactly as they appear. The parsed coverage for this issuer holds these 6 filings; a 5% holder that has not filed in the covered window would not appear here.
• Congress lens: Senate PTR archive and House PTR archive as maintained on this site. The combined record (as of October 3, 2026), the House aggregate (as of October 3, 2026) and the Senate aggregate (as of October 1, 2026) each carry no row for this ticker. This audit therefore reports no recorded congressional trade in those aggregates; it does not reconstruct individual filers, and an absence in the aggregates is reported as an absence in the aggregates, not as proof about any individual filing.
• Short interest lens: FINRA Equity Short Interest files (biweekly settlement dates), collected directly from FINRA's public distribution. The published series covers 137 settlements from January 15, 2021 (16,552,268 shares) to September 15, 2026. The latest reading is 16,123,980 shares on September 15, 2026, down 10.99% from the prior settlement (18,114,651 on August 31, 2026). The series maximum is 42,521,469 shares on January 12, 2024 (verified by a maximum query over the series, not read off the latest row), so the latest reading sits 62.1% below a record set in 2024. The year-ago settlement (September 15, 2025) printed 23,623,517 shares, so the latest reading sits 31.7% below a year ago. The series minimum is 10,200,224 shares on February 28, 2022. The June 30, 2026 settlement printed 19,938,997 shares, so the latest reading sits 19.1% below the 13F snapshot date's borrow. FINRA publishes each settlement about two weeks after the fact, so the October price action is not yet in this series. The share-count ratio (1.26%) uses the fundamentals file's shares-outstanding figure below.
• Fundamentals note: our fundamentals collection carries CVS Health's revenue of $402,067,000,000, net income of $1,768,000,000 and assets of $253,538,000,000, each labelled fiscal 2025 in the file. The file is marked ok for this name, with no missing fields: shares outstanding of 1,278,970,369 (as of July 29, 2026 in the file, sourced in the file to the share count) and a file-computed market value of $110,541,409,382.98. The file does not flag the issuer as a foreign private issuer, and it carries SIC 5912, Retail-Drug Stores and Proprietary Stores. The file's price for the name is $86.43 as of October 6, 2026; our daily-close file ends October 2, 2026 at $86.46, and we keep the two files' figures separate rather than blending them.
• Prices: our own daily-close file for CVS Health through October 2, 2026 ($86.46 close, +8.9% year to date on that file; 252-session closing high $110.60 on July 21, 2026, so the last close sits 21.8% below it; 252-session closing low $70.08 on March 27, 2026, so the last close sits 23.4% above it; closes of $71.82 at March 31, 2026 and $103.45 at June 30, 2026, a second-quarter change of +44.0%; change from June 30 to October 2 of -16.4%; change from the September 30, 2025 close of $75.39 of +14.7%). The series in our price file begins June 1, 2021 at $85.87 and holds 1,342 rows.
• Market context sources: Google Trends United States list via a trends mirror ("cvs" the top entry at 1,000+ searches, and the only entry naming a listed company; list checked October 14, 2026); AltIndex meme-stocks list (checked October 14, 2026; its top name was set aside in this series in 2026 for missing lenses, re-checked today with the same result — see the selection note in the data sheet); a Justice Department settlement of $315 million announced October 13, 2026, resolving a case over opioid prescriptions, with the company saying it disagreed with the allegations and admitted no wrongdoing, as carried by Reuters and the Associated Press reporting, checked October 14, 2026; second-quarter 2026 results reported August 5, 2026 (revenue of $106.1 billion, up 7.3% year over year; adjusted earnings per share of $2.58 against a consensus near $1.87; full-year adjusted guidance raised to $7.90–$8.10), as carried by multiple outlets, checked October 14, 2026; Cardinal Health extending its distribution agreement with CVS through June 30, 2032, announced October 1, 2026, as carried by multiple outlets, checked October 14, 2026; MarketBeat consensus of moderate buy with an average target of $107.80, and Leerink Partners cutting its target from $119 to $112 on October 12, 2026 while keeping an outperform rating, as carried by MarketBeat reporting, checked October 14, 2026; third-quarter results scheduled for November 4, 2026, as carried by multiple outlets, checked October 14, 2026. Figures we could not confirm against two sources were left out; the external items above are reported speech from those outlets, not GetCoattail measurements.
• CVS Health is in the GetCoattail stock-page universe: CVS Health Corporation (CVS) stock page. Series data: cvs_lens_data.csv · cvs_short_interest_series.csv. Earlier audits: Nebius · Take-Two.

Past patterns are not a promise of future results. For education only — not investment advice.

This article describes public filings as of the dates stated. It is not investment advice and makes no recommendation. Filings lag reality: 13F positions are as of June 30, 2026, and later trading is not yet public.

Revision history

• v1.0 — October 14, 2026: first publication.